Current strategies for the treatment of Alzheimer's disease and other tauopathies

Expert Opinion on Therapeutic Targets

Volumn 10, Issue 5, 2006, Pages 665-676

  Dickey, Chad A ^a   Petrucelli, Leonard ^a  

^a MAYO GRADUATE SCHOOL   (United States)

Author keywords

Aggregation; Chaperone; Heat shock; Kinase; Phosphorylation; Tau

Indexed keywords

AMANTADINE; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN ANTIBODY; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; AMYLOID PROTEIN; ARA 014418; BETA SECRETASE INHIBITOR; BUTYROLACTONE; CHELATING AGENT; CHOLINESTERASE INHIBITOR; CYCLIN DEPENDENT KINASE INHIBITOR; ENDOTHELIN CONVERTING ENZYME INHIBITOR; GAMMA SECRETASE INHIBITOR; GLYCOGEN SYNTHASE KINASE 3 INHIBITOR; HYMENIALDISINE; INDIRUBIN; LITHIUM CHLORIDE; MALEIMIDE DERIVATIVE; MEMBRANE METALLOENDOPEPTIDASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; PAULLONE DERIVATIVE; PHENOTHIAZINE; PROTEIN KINASE INHIBITOR; PROTEINASE INHIBITOR; ROSCOVITINE; TAU PROTEIN; TUNGSTATE SODIUM; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALZHEIMER DISEASE; CELL LOSS; CHROMOSOME 17; CLINICAL TRIAL; DEGENERATIVE DISEASE; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG MECHANISM; DRUG TARGETING; FRONTOTEMPORAL DEMENTIA; GLIOSIS; HUMAN; MUTATIONAL ANALYSIS; NERVE CELL; NEUROFIBRILLARY TANGLE; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PARKINSONISM; PROTEIN AGGREGATION; PROTEIN FOLDING; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION; TAUOPATHY;

ALZHEIMER DISEASE; ANIMALS; DRUG DELIVERY SYSTEMS; HUMANS; TAU PROTEINS; TAUOPATHIES;

EID: 33749241872     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.10.5.665     Document Type: Review

References (122)

1. HUTTON M, LENDON CL, RIZZU P et al.: Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17. Nature (1998) 393(6686):702-705.
2. SPILLANTINI MG, MURRELL JR, GOEDERT M et al.: Mutation in the tau gene in familial multiple system tauopathy with presenile dementia. Proc. Natl. Acad. Sci. USA (1998) 95(13):7737-7741.
3. MARJAUX E, HARTMANN D, DE STROOPER B: Presenilins in memory, Alzheimer's disease, and therapy. Neuron (2004) 42(2):189-192.
4. OHNO M, SAMETSKY EA, YOUNKIN LH et al.: BACE1 deficiency rescues memory deficits and cholinergic dysfunction in a mouse model of alzheimer's disease. Neuron (2004) 41(1):27-33.
5. WEGGEN S, ERIKSEN JL, DAS P et al.: A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature (2001) 414(6860):212-216.
6. CUAJUNGCO MP, FAGET KY, HUANG X, TANZI RE, BUSH AI: Metal chelation as a potential therapy for Alzheimer's disease. Ann. NY Acad. Sci. (2000) 920:292-304.
7. CARSON JA, TURNER AJ: Beta-amyloid catabolism: roles for neprilysin (NEP) and other metallopeptidases? J. Neurochem. (2002) 81(1):1-8.
8. SANTACRUZ K, LEWIS J, SPIRES T et al.: Tau suppression in a neurodegenerative mouse model improves memory function. Science (2005) 309(5733):476-481.
9. ST GEORGE-HYSLOP PH, TANZI RE, POLINSKY RJ et al.: The genetic defect causing familial Alzheimer's disease maps on chromosome 21. Science (1987) 235(4791):885-890.
10. GOATE A, CHARTIER-HARLIN MC, MULLAN M et al.: Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature (1991) 349(6311):704-706.
11. MULLAN M, HOULDEN H, WINDELSPECHT M et al.: A locus for familial early-onset Alzheimer's disease on the long arm of chromosome 14, proximal to the alpha 1-antichymotrypsin gene. Nat. Genet. (1992) 2(4):340-342.
12. SHERRINGTON R, ROGAEV EI, LIANG Y et al.: Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature (1995) 375(6534):754-760.
13. MASTERS CL, SIMMS G, WEINMAN NA et al.: Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc. Natl. Acad. Sci. USA (1985) 82(12):4245-4249.
14. ROBAKIS NK, WISNIEWSKI HM, JENKINS EC et al.: Chromosome 21q21 sublocalisation of gene encoding beta-amyloid peptide in cerebral vessels and neuritic (senile) plaques of people with Alzheimer disease and Down syndrome. Lancet (1987) 1(8529):384-385.
15. GOMEZ-ISLA T, HOLLISTER R, WEST H et al.: Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease. Ann. Neurol. (1997) 41(1):17-24.
16. BRAAK H, BRAAK E: Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. (Berl) (1991) 82(4):239-259.
17. GRUNDKE-IQBAL I, IQBAL K, TUNG YC et al.: Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc. Natl. Acad. Sci. USA (1986) 83(13):4913-4917.
18. IHARA Y, NUKINA N, MIURA R, OGAWARA M: Phosphorylated tau protein is integrated into paired helical filaments in Alzheimer's disease. J. Biochem. (Tokyo) (1986) 99(6):1807-1810.
19. CRYSTAL H, DICKSON D, FULD P et al.: Clinico-pathologic studies in dementia: nondemented subjects with pathologically confirmed Alzheimer's disease. Neurology (1988) 38(11):1682-1687.
20. FEANY MB, DICKSON DW: Neurodegenerative disorders with extensive tau pathology: a comparative study and review. Ann. Neurol. (1996) 40(2):139-148.
21. DUMANCHIN C, CAMUZAT A, CAMPION D et al.: Segregation of a missense mutation in the microtubule-associated protein tau gene with familial frontotemporal dementia and parkinsonism. Hum. Mol. Genet. (1998) 7(11):1825-1829.
22. GROVER A, HOULDEN H, BAKER M et al.: 5′ splice site mutations in tau associated with the inherited dementia FTDP-17 affect a stem-loop structure that regulates alternative splicing of exon 10. J. Biol. Chem. (1999) 274(21):15134-15143.
23. BAKER M, LITVAN I, HOULDEN H et al.: Association of an extended haplotype in the tau gene with progressive supranuclear palsy. Hum. Mol. Genet. (1999) 8(4):711-715.
24. KWOK JB, TEBER ET, LOY C et al.: Tau haplotypes regulate transcription and are associated with Parkinson's disease. Ann. Neurol. (2004) 55(3):329-334.
25. SKIPPER L, WILKES K, TOFT M et al.: Linkage disequilibrium and association of MAPT H1 in Parkinson disease. Am. J. Hum. Genet. (2004) 75(4):669-677.
26. GOEDERT M, SPILLANTINI MG, SERPELL LC et al.: From genetics to pathology: tau and alpha-synuclein assemblies in neurodegenerative diseases. Philos. Trans. R. Soc. Lond. B. Biol. Sci. (2001) 356(1406):213-227.
27. RADEMAKERS R, MELQUIST S, CRUTS M et al.: High-density SNP haplotyping suggests altered regulation of tau gene expression in progressive supranuclear palsy. Hum. Mol. Genet. (2005) 14(21):3281-3292.
28. KLEIN RL, LIN WL, DICKSON DW et al.: Rapid neurofibrillary tangle formation after localized gene transfer of mutated tau. Am. J. Pathol. (2004) 164(1):347-353.
29. LANE RM, KIVIPELTO M, GREIG NH: Acetylcholinesterase and its inhibition in Alzheimer disease. Clin. Neuropharmacol. (2004) 27(3):141-149.
30. RACCHI M, MAZZUCCHELLI M, PORRELLO E, LANNI C, GOVONI S: Acetylcholinesterase inhibitors: novel activities of old molecules. Pharmacol. Res. (2004) 50(4):441-451.
31. REISBERG B, DOODY R, STOFFLER A et al.: Memantine in moderace-to-severe Alzheimer's disease. N. Engl. J. Med. (2003) 348(14):1333-1341.
32. LIPTON SA: Paradigm shift in NMDA receptor antagonist drug development: molecular mechanism of uncompetitive inhibition by memantine in the treatment of Alzheimer's disease and other neurologic disorders. J. Alzheimers Dis. (2004) 6(6 Suppl.):S61-S74.
33. FISCHER PA, JACOBI P, SCHNEIDER E, SCHONBERGER B: [Effects of intravenous administration of memantine in parkinsonian patients (author's transl)]. Arzneimittelforschung (1977) 27(7):1487-1489.
34. READING PJ, LUCE AK, MCKEITH IG: Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: preliminary findings from an open trial. Mov. Disord. (2001) 16(6):1171-1174.
35. TOURTELLOTTE WW, POTVIN AR, SYNDULKO K et al.: Parkinson's disease: Cogentin with Sinemet, a better response. Prog. Neuropsychopharmacol. Biol. Psychiatry (1982) 6(1):51-55.
36. PAKKENBERG H, BIRKET-SMITH E, DUPONT E et al.: Parkinson's disease treated with Sinemet or Madopar. A controlled multicenter trial. Acta Neurol. Scand. (1976) 53(5):376-385.
37. FRANCIS PT, NORDBERG A, ARNOLD SE: A preclinical view of cholinesterase inhibitors in neuroprotection: do they provide more than symptomatic benefits in Alzheimer's disease? Trends Pharmacol. Sci. (2005) 26(2):104-111.
38. CACCAMO A, ODDO S, BILLINGS LM et al.: M1 receptors play a central role in modulating AD-like pathology in transgenic mice. Neuron (2006) 49(5):671-682.
39. FORLENZA OV, SPINK JM, DAYANANDAN R et al.: Muscarinic agonists reduce tau phosphorylation in non-neuronal cells via GSK-3beta inhibition and in neurons. J. Neural Transm. (2000) 107(10):1201-1212.
40. KUMAR R, LOZANO AM, KIM YJ et al.: Double-blind evaluation of subthalamic nucleus deep brain stimulation in advanced Parkinson's disease. Neurology (1998) 51(3):850-855.
41. JANTZEN PT, CONNOR KE, DICARLO G et al.: Microglial activation and beta-amyloid deposit reduction caused by a nitric oxide-releasing nonsteroidal anti-inflammatory drug in amyloid precursor protein plus presenilin-1 transgenic mice. J. Neurosci. (2002) 22(6):2246-2254.
42. SCHENK D, BARBOUR R, DUNN W et al.: Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature (1999) 400(6740):173-177.
43. WILCOCK DM, ROJIANI A, ROSENTHAL A et al.: Passive immunotherapy against Abeta in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage. J. Neuroinflammation (2004) 1(1):24.
44. ECKMAN EA, ECKMAN C: Aβ metabolism and Alzheimer's disease. Landes Biosciences (2003):7.
45. ECKMAN EA, ECKMAN CB: Abeta-degrading enzymes: modulators of Alzheimer's disease pathogenesis and targets for therapeutic intervention. Biochem. Soc. Trans. (2005) 33(Pt 5):1101-1105.
46. ODDO S, BILLINGS L, KESSLAK JP, CRIBBS DH, LAFERLA FM: Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron (2004) 43(3):321-332.
47. POLYMEROPOULOS MH, LAVEDAN C, LEROY E et al.: Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science (1997) 276(5321):2045-2047.
48. KRUGER R, KUHN W, MULLER T et al.: Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat. Genet. (1998) 18(2):106-108.
49. SINGLETON AB, FARRER M, JOHNSON J et al.: alpha-Synuclein locus triplication causes Parkinson's disease. Science (2003) 302(5646):841.
50. KITADA T, ASAKAWA S, HATTORI N et al.: Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature (1998) 392(6676):605-608.
51. VALENTE EM, ABOU-SLEIMAN PM, CAPUTO V et al.: Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science (2004) 304(5674):1158-1160.
52. ZIMPRICH A, BISKUP S, LEITNER P et al.: Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron (2004) 44(4):601-607.
53. PAISAN-RUIZ C, JAIN S, EVANS EW et al.: Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron (2004) 44(4):595-600.
54. BONIFATI V, RIZZU P, VAN BAREN MJ et al.: Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science (2003) 299(5604):256-259.
55. PRZEDBORSKI S, VILA M: The 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridi ne mouse model: a tool to explore the pathogenesis of Parkinson's disease. Ann. NY Acad. Sci. (2003) 991:189-198.
56. BETARBET R, SHERER TB, MACKENZIE G et al.: Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat. Neurosci. (2000) 3(12):1301-1306.
57. ANDORFER C, KRESS Y, ESPINOZA M et al.: Hyperphosphorylation and aggregation of tau in mice expressing normal human tau isoforms. J. Neurochem. (2003) 86(3):582-590.
58. MENENDEZ J, RODRIGUEZ-NAVARRO JA, SOLANO RM et al.: Suppression of Parkin enhances nigrostriatal and motor neuron lesion in mice over-expressing human-mutated tau protein. Hum. Mol. Genet. (2006) 15(13):2045-2058.
59. KLEIN RL, DAYTON RD, HENDERSON KM, PETRUCELLI L: Parkin is protective for substantia nigra dopamine neurons in a tau gene transfer neurodegeneration model. Neurosci. Lett. (2006) 401(1-2):130-135.
60. TUCKER KL, MEYER M, BARDE YA: Neurotrophins are required for nerve growth during development. Nat. Neurosci. (2001) 4(1):29-37.
61. HARADA A, OGUCHI K, OKABE S et al.: Altered microtubule organization in small-calibre axons of mice lacking tau protein. Nature (1994) 369(6480):488-491.
62. DAWSON HN, FERREIRA A, EYSTER MV et al.: Inhibition of neuronal maturation in primary hippocampal neurons from tau deficient mice. J. Cell Sci. (2001) 114(Pt 6):1179-1187.
63. KAR S, FAN J, SMITH MJ, GOEDERT M, AMOS LA: Repeat motifs of tau bind to the insides of microtubules in the absence of taxol. EMBO J. (2003) 22(1):70-77.
64. ZHANG B, MAITI A, SHIVELY S et al.: Microtubule-binding drugs offset tau sequestration by stabilizing microtubules and reversing fast axonal transport deficits in a tauopathy model. Proc. Natl. Acad. Sci. USA (2005) 102(1):227-231.
65. DICKEY CA, ERIKSEN J, KAMAL A et al.: Development of a high throughput drug screening assay for the detection of changes in tau levels - proof of concept with HSP90 inhibitors. Curr. Alzheimer Res. (2005) 2(2):231-238.
66. DICKEY CA, DUNMORE J, LU B et al.: HSP induction mediates selective clearance of tau phosphorylated at proline-directed Ser/Thr sites but not KXGS (MARK) sites. FASEB J. (2006) 20(6):753-755.
67. NOBLE W, PLANEL E, ZEHR C et al.: Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. Proc. Natl. Acad. Sci. USA (2005) 102(19):6990-6995.
68. DREWES G, EBNETH A, PREUSS U, MANDELKOW EM, MANDELKOW E: MARK, a novel family of protein kinases that phosphorylate microtubule-associated proteins and trigger microtubule disruption. Cell (1997) 89(2):297-308.
69. SONTAG E, NUNBHAKDI-CRAIG V, LEE G, BLOOM GS, MUMBY MC: Regulation of the phosphorylation state and microtubule-binding activity of Tau by protein phosphatase 2A. Neuron (1996) 17(6):1201-1207.
70. NISHIMURA I, YANG Y, LU B: PAR-1 kinase plays an initiator role in a temporally ordered phosphorylation process that confers tau toxicity in Drosophila. Cell (2004) 116(5):671-682.
71. SPERBER BR, LEIGHT S, GOEDERT M, LEE VM: Glycogen synthase kinase-3 beta phosphorylates tau protein at multiple sites in intact cells. Neurosci. Lett. (1995) 197(2):149-153.
72. BAUMANN K, MANDELKOW EM, BIERNAT J, PIWNICA-WORMS H, MANDELKOW E: Abnormal Alzheimer-like phosphorylation of tau-protein by cyclin-dependent kinases cdk2 and cdk5. FEBS Lett. (1993) 336(3):417-424.
73. RODER HM, EDEN PA, INGRAM VM: Brain protein kinase PK40erk converts tau into a PHF-like form as found in Alzheimer's disease. Biochem. Biophys. Res. Commun. (1993) 193(2):639-647.
74. BHAT R, XUE Y, BERG S et al.: Structural insights and biological effects of glycogen synthase kinase 3-specific inhibitor AR-A014418. J. Biol. Chem. (2003) 278(46):45937-45945.
75. COHEN P, GOEDERT M: GSK3 inhibitors: development and therapeutic potential. Nat. Rev. Drug Discov. (2004) 3(6):479-487.
76. MEIJER L, THUNNISSEN AM, WHITE AW et al.: Inhibition of cyclin-dependent kinases, GSK-3beta and CK1 by hymenialdisine, a marine sponge constituent. Chem. Biol. (2000) 7(1):51-63.
77. ENGLER TA, MALHOTRA S, BURKHOLDER TP et al.: The development of potent and selective bisarylmaleimide GSK3 inhibitors. Bioorg. Med. Chem. Lett. (2005) 15(4):899-903.
78. LEOST M, SCHULTZ C, LINK A et al.: Paullones are potent inhibitors of glycogen synthase kinase-3beta and cyclin-dependent kinase 5/p25. Eur. J. Biochem. (2000) 267(19):5983-5994.
79. LECLERC S, GARNIER M, HOESSEL R et al.: Indirubins inhibit glycogen synthase kinase-3 beta and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease. A property common to most cyclin-dependent kinase inhibitors? J. Biol. Chem. (2001) 276(1):251-260.
80. GOMEZ-RAMOS A, DOMINGUEZ J, ZAFRA D et al.: Sodium tungstate decreases the phosphorylation of tau through GSK3 inactivation. J. Neurosci. Res. (2006) 83(2):264-273.
81. ALVAREZ A, TORO R, CACERES A, MACCIONI RB: Inhibition of tau phosphorylating protein kinase cdk5 prevents beta-amyloid-induced neuronal death. FEBS Lett. (1999) 459(3):421-426.
82. KITAZAWA M, ODDO S, YAMASAKI TR, GREEN KN, LAFERLA FM: Lipopolysaccharide-induced inflammation exacerbates tau pathology by a cyclin-dependent kinase 5-mediated pathway in a transgenic model of Alzheimer's disease. J. Neurosci. (2005) 25(39):8843-8853.
83. RAPOPORT M, FERREIRA A: PD98059 prevents neurite degeneration induced by fibrillar beta-amyloid in mature hippocampal neurons. J. Neurochem. (2000) 74(1):125-133.
84. LE CORRE S KH, KLAFKI HW, HÜBINGER G et al.: An inhibitor of tau hyperphosphorylation prevents severe motor impairments in tau transgenic mice. Proc. Natl. Acad. Sci. USA (2006) 103(25):9673-9678.
85. WISCHIK CM, EDWARDS PC, LAI RY, ROTH M, HARRINGTON CR: Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazines. Proc. Natl. Acad. Sci. USA (1996) 93(20):11213-11218.
86. PICKHARDT M, GAZOVA Z, VON BERGEN M et al.: Anthraquinones inhibit tau aggregation and dissolve Alzheimer's paired helical filaments in vitro and in cells. J. Biol. Chem. (2005) 280(5):3628-3635.
87. NECULA M, CHIRITA CN, KURET J: Cyanine dye N744 inhibits tau fibrillization by blocking filament extension: implications for the treatment of tauopathic neurodegenerative diseases. Biochemistry (2005) 44(30):10227-10237.
88. TANIGUCHI T, SUMIDA M, HIRAOKA S et al.: Effects of different anti-tau antibodies on tau fibrillogenesis: RTA-1 and RTA-2 counteract tau aggregation. FEBS Lett. (2005) 579(6):1399-1404.
89. LEE HG, PERRY G, MOREIRA PI et al.: Tau phosphorylation in Alzheimer's disease: pathogen or protector? Trends Mol. Med. (2005) 11(4):164-169.
90. JIANG Z, TANG H, HAVLIOGLU N et al.: Mutations in tau gene exon 10 associated with FTDP-17 alter the activity of an exonic splicing enhancer to interact with Tra2 beta. J. Biol. Chem. (2003) 278(21):18997-19007.
91. HARTMANN AM, RUJESCU D, GIANNAKOUROS T et al.: Regulation of alternative splicing of human tau exon 10 by phosphorylation of splicing factors. Mol. Cell. Neurosci. (2001) 18(1):80-90.
92. TROJANOWSKI JQ, LEE VM: Pathological tau: a loss of normal function or a gain in toxicity? Nat. Neurosci. (2005) 8(9):1136-1137.
93. MICHAELIS ML, SEYB KI, ANSAR S: Cytoskeletal integrity as a drug target. Curr Alzheimer Res (2005) 2(2):227-229.
94. YOUNG JC, AGASHE VR, SIEGERS K, HARTL FU: Pathways of chaperone-mediated protein folding in the cytosol. Nat. Rev. Mol. Cell. Biol. (2004) 5(10):781-791.
95. NECKERS L, IVY SP: Heat shock protein 90. Curr. Opin. Oncol. (2003) 15(6):419-424.
96. MULLER P, CESKOVA P, VOJTESEK B: Hsp90 is essential for restoring cellular functions of temperature-sensitive p53 mutant protein but not for stabilization and activation of wild-type p53: implications for cancer therapy. J. Biol. Chem. (2005) 280(8):6682-6691.
97. MAYER MP, NIKOLAY R, BUKAU B: Aha, another regulator for hsp90 chaperones. Mol. Cell (2002) 10(6):1255-1256.
98. YOUNG JC, HARTL FU: Polypeptide release by Hsp90 involves ATP hydrolysis and is enhanced by the co-chaperone p23. EMBO J. (2000) 19(21):5930-5940.
99. XU W, MARCU M, YUAN X et al.: Chaperone-dependent E3 ubiquitin ligase CHIP mediates a degradative pathway for c-ErbB2/Neu. Proc. Natl. Acad. Sci. USA (2002) 99(20):12847-12852.
100. YOUNG JC, MOAREFI I, HARTL FU: Hsp90: a specialized but essential protein-folding tool. J. Cell Biol. (2001) 154(2):267-273.
101. PANARETOU B, PRODROMOU C, ROE SM et al.: ATP binding and hydrolysis are essential to the function of the Hsp90 molecular chaperone in vivo. EMBO J. (1998) 17(16):4829-4836.
102. CIECHANOVER A, BRUNDIN P: The ubiquicin proteasome system in neurodegenerative diseases: sometimes the chicken, sometimes the egg. Neuron (2003) 40(2):427-446.
103. ZHANG Y, GAO J, CHUNG KK et al.: Parkin functions as an E2-dependent ubiquitin-protein ligase and promotes the degradation of the synaptic vesicle-associated protein, CDCrel-1. Proc. Natl. Acad. Sci. USA (2000) 97(24):13354-13359.
104. DAVIES SW, TURMAINE M, COZENS BA et al.: Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell (1997) 90(3):537-548.
105. DOU F, NETZER WJ, TANEMURA K et al.: Chaperones increase association of tau protein with microtubules. Proc. Natl. Acad. Sci. USA (2003) 100(2):721-726.
106. SHIMURA H, MIURA-SHIMURA Y, KOSIK KS: Binding of tau to heat shock protein 27 leads to decreased concentration of hyperphosphorylated tau and enhanced cell survival. J. Biol. Chem. (2004) 279(17):17957-17962.
107. PETRUCELLI L, DICKSON D, KEHOE K et al.: CHIP and Hsp70 regulate tau ubiquitination, degradation and aggregation. Hum. Mol. Genet. (2004) 13(7):703-714.
108. SHIMURA H, SCHWARTZ D, GYGI SP, KOSIK KS: CHIP-Hsc70 complex ubiquitinates phosphorylated tau and enhances cell survival. J. Biol. Chem. (2004) 279(6):4869-4876.
109. DICKEY C, YUE M, LIN WL et al.: Deletion of the ubiquitin ligase CHIP leads to the accumulation, but not the aggregation, of both endogenous phospho-and caspase-3-cleaved tau species. J. Neurosci. (2006) 26(26):6985-6996.
110. DAI Q, ZHANG C, WU Y et al.: CHIP activates HSF1 and confers protection against apoptosis and cellular stress. EMBO J. (2003) 22(20):5446-5458.
111. OTT A, STOLK RP, VAN HARSKAMP F et al.: Diabetes mellitus and the risk of dementia: The Rotterdam Study. Neurology (1999) 53(9):1937-1942.
112. ELLIOTT E, ATLAS R, LANGE A, GINZBURG I: Brain-derived neurotrophic factor induces a rapid dephosphorylation of tau protein through a PI-3 kinase signalling mechanism. Eur. J. Neurosci. (2005) 22(5):1081-1089.
113. FREUDE S, PLUM L, SCHNITKER J et al.: Peripheral hyperinsulinemia promotes tau phosphorylation in vivo. Diabetes (2005) 54(12):3343-3348.
114. DILLIN A, CRAWFORD DK, KENYON C: Timing requirements for insulin/IGF-1 signaling in C. elegans. Science (2002) 298(5594):830-834.
115. MORLEY JF, MORIMOTO RI: Regulation of longevity in Caenorhabditis elegans by heat shock factor and molecular chaperones. Mol. Biol. Cell (2004) 15(2):657-664.
116. HSU AL, MURPHY CT, KENYON C: Regulation of aging and age-related disease by DAF-16 and heat-shock factor. Science (2003) 300(5622):1142-1145.
117. GLANNAKOU ME, GOSS M, JUNGER MA et al.: Long-lived Drosophila with overexpressed dFOXO in adult fat body. Science (2004) 305(5682):361.
118. HUNG KS, HWANG SL, LIANG CL et al.: Calpain inhibitor inhibits p35-p25-Cdk5 activation, decreases tau hyperphosphorylation, and improves neurological function after spinal cord hemisection in rats. J. Neuropathol. Exp. Neurol. (2005) 64(1):15-26.
119. SHENG JG, ZHU SG, JONES RA, GRIFFIN WS, MRAK RE: Interleukin-1 promotes expression and phosphorylation of neurofilament and tau proteins in vivo. Exp. Neurol. (2000) 163(2):388-391.
120. QUINTANILLA RA, ORELLANA DI, GONZALEZ-BILLAULT C, MACCIONI RB: Interleukin-6 induces Alzheimer-type phosphorylation of tau protein by deregulating the cdk5/p35 pathway. Exp. Cell Res. (2004) 295(1):245-257.
121. XIA M, HYMAN BT: GROalpha/KC, a chemokine receptor CXCR2 ligand, can be a potent trigger for neuronal ERK1/2 and PI-3 kinase pathways and for tau hyperphosphorylation - a role in Alzheimer's disease? J. Neuroimmunol. (2002) 122(1-2):55-64.
122. RAPOPORT M, DAWSON HN, BINDER LI, VITEK MP, FERREIRA A: Tau is essential to beta-amyloid-induced neurotoxicity. Proc. Natl. Acad. Sci. USA (2002) 99(9):6364-6369.